Reporter brief
Metformin's effect on aging markers in prediabetic individuals: RCT protocol description
What happened
This document describes the protocol for a randomized controlled trial investigating whether metformin treatment affects aging-related biomarkers in prediabetic subjects from North India. The study planned to compare 6 months of metformin versus placebo and measure telomere length, telomerase activity, and expression of longevity-related genes (SIRT1, p66Shc, p53, mTOR) in blood cells. No results or outcome data are reported.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Pre-diabetic individuals from North India
- Design
- Rct
- Sample
- —
- Journal
- Diabetes Foundation, India
- Published
- Dec 24, 2025
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.